Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation

Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Magro, Fernando, Afonso, Joana, Lopes, Susana, Coelho, Rosa, Gonçalves, Raquel, Caldeira, Paulo, Lago, Paula, de Sousa, Helena Tavares, Ramos, Jaime, Gonçalves, Ana Rita, Ministro, Paula, Rosa, Isadora, Vieira, Ana Isabel, Andrade, Patrícia, Soares, João-Bruno, Carvalho, Diana, Sousa, Paula, Meira, Tânia, Lopes, Joanne, Moleiro, Joana, Dias, Cláudia Camila, Falcão, Amílcar, Geboes, Karel, Carneiro, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514398/
https://www.ncbi.nlm.nih.gov/pubmed/28629912
http://dx.doi.org/10.1016/j.ebiom.2017.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514398/
https://www.ncbi.nlm.nih.gov/pubmed/28629912
http://dx.doi.org/10.1016/j.ebiom.2017.06.004

Ejemplares similares